Mephenytoin

Summary

Mephenytoin (CHEMBL861) is an approved small-molecule anticonvulsant (ATC N03AB04); indicated across 1 condition including epilepsy.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N03AB04 (+1 more)
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 218.25 Da · C12H14N2O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL861
Name	Mephenytoin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4060
ChEBI	CHEBI:6757
ATC	N03AB04, N03AB54
Molecular formula	C12H14N2O2
Molecular weight	218.25
InChIKey	GMHKMTDVRCWUDX-UHFFFAOYSA-N

SMILES: CCC1(C(=O)N(C(=O)N1)C)C2=CC=CC=C2

IUPAC name: 5-ethyl-3-methyl-5-phenylimidazolidine-2,4-dione

ChEBI definition: An imidazolidine-2,4-dione (hydantoin) in which the imidazolidine nucleus carries a methyl group at N-3 and has ethyl and phenyl substituents at C-5. An anticonvulsant, it is no longer available in the USA or the UK but is still studied largely because of its interesting hydroxylation polymorphism.

Pharmacological roles (ChEBI): anticonvulsant.

Also known as: Mefenitoina, Mephenytoin, Mephenytoine, Mesantoin, Methoin, NSC-34652, SID56463168, MEPHENYTOIN, mephenytoin

Patent coverage: 2,006 distinct patent families (6,385 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Cytochrome P450 2C19.

Bioactivity

ChEMBL activities: 5 potent at pChembl ≥ 5 of 5 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CYP2C19	5.96	IC50	1110	nM	CHEMBL_ACT_24740407
CYP2C19	5.9	IC50	1260	nM	CHEMBL_ACT_24822373
CYP2C19	5.9	IC50	1260	nM	CHEMBL_ACT_25593407
CYP2C19	5.86	IC50	1380	nM	CHEMBL_ACT_25502131
CYP2C19	5.6	IC50	2500	nM	CHEMBL_ACT_26109718

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
epilepsy	4	MONDO:0005027	EFO:0000474

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00162383	Not specified	UNKNOWN	Metabolic Capacity of Israeli Populations

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 10 clinical and 88 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).